Total Payments
$130,602
2023 Payments
$865.92
Companies
5
Transactions
27
Payment Breakdown by Category
Research$120,931 (92.6%)
Travel$9,220 (7.1%)
Food & Beverage$451.50 (0.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $120,931 | 13 | 92.6% |
| Travel and Lodging | $9,220 | 8 | 7.1% |
| Food and Beverage | $451.50 | 6 | 0.3% |
Payments by Type
Research
$120,931
13 transactions
General
$9,671
14 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Valneva Austria GmbH | $120,065 | 12 | $0 (2022) |
| SANOFI-AVENTIS U.S. LLC | $7,460 | 5 | $0 (2017) |
| AstraZeneca Pharmaceuticals LP | $2,176 | 8 | $0 (2019) |
| PFIZER INC. | $865.92 | 1 | $0 (2023) |
| Merck Sharp & Dohme LLC | $35.00 | 1 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $865.92 | 1 | PFIZER INC. ($865.92) |
| 2022 | $120,100 | 13 | Valneva Austria GmbH ($120,065) |
| 2019 | $2,176 | 8 | AstraZeneca Pharmaceuticals LP ($2,176) |
| 2017 | $7,460 | 5 | SANOFI-AVENTIS U.S. LLC ($7,460) |
All Payment Transactions
27 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 08/24/2023 | PFIZER INC. | ZAVZPRET (Drug) | — | Cash or cash equivalent | $865.92 | Research |
| Study: A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION • Category: PAIN | ||||||
| 11/21/2022 | Valneva Austria GmbH | — | — | Cash or cash equivalent | $1,500.00 | Research |
| Study: A MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLINDED PIVOTAL STUDY TO EVALUATE SAFETY AND IMMUNOGENICITY OF A LIVE-ATTEUATED CHIKUNGUNYA VIRUS VACCINE CANDIDATE (VLA1553) IN ADULTS AGED 18 YEARS AND ABOVE | ||||||
| 10/06/2022 | Valneva Austria GmbH | — | — | Cash or cash equivalent | $17,768.28 | Research |
| Study: A MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLINDED PIVOTAL STUDY TO EVALUATE SAFETY AND IMMUNOGENICITY OF A LIVE-ATTEUATED CHIKUNGUNYA VIRUS VACCINE CANDIDATE (VLA1553) IN ADULTS AGED 18 YEARS AND ABOVE | ||||||
| 06/15/2022 | Merck Sharp & Dohme LLC | CAPVAXIVE (Biological) | Food and Beverage | In-kind items and services | $35.00 | General |
| Category: VACCINE | ||||||
| 04/26/2022 | Valneva Austria GmbH | — | — | Cash or cash equivalent | $5,075.00 | Research |
| Study: A RANDOMIZED, DOUBLE-BLINDED PHASE 3 STUDY TO DEMONSTRATE LOT-TO-LOT CONSISTENCY OF THREE LOTS OF A LIVE-ATTENUATED CHIKUNGUNYA VIRUS VACCINE CANDIDATE (VLA1553) IN HEALTHY ADULTS AGED 18 TO 45 YEARS | ||||||
| 04/12/2022 | Valneva Austria GmbH | — | — | Cash or cash equivalent | $45,726.00 | Research |
| Study: A MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLINDED PIVOTAL STUDY TO EVALUATE SAFETY AND IMMUNOGENICITY OF A LIVE-ATTEUATED CHIKUNGUNYA VIRUS VACCINE CANDIDATE (VLA1553) IN ADULTS AGED 18 YEARS AND ABOVE | ||||||
| 04/12/2022 | Valneva Austria GmbH | — | — | Cash or cash equivalent | $26,802.00 | Research |
| Study: A RANDOMIZED, DOUBLE-BLINDED PHASE 3 STUDY TO DEMONSTRATE LOT-TO-LOT CONSISTENCY OF THREE LOTS OF A LIVE-ATTENUATED CHIKUNGUNYA VIRUS VACCINE CANDIDATE (VLA1553) IN HEALTHY ADULTS AGED 18 TO 45 YEARS | ||||||
| 04/05/2022 | Valneva Austria GmbH | — | — | Cash or cash equivalent | $6,370.00 | Research |
| Study: A MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLINDED PIVOTAL STUDY TO EVALUATE SAFETY AND IMMUNOGENICITY OF A LIVE-ATTEUATED CHIKUNGUNYA VIRUS VACCINE CANDIDATE (VLA1553) IN ADULTS AGED 18 YEARS AND ABOVE | ||||||
| 03/29/2022 | Valneva Austria GmbH | — | — | Cash or cash equivalent | $3,350.00 | Research |
| Study: A RANDOMIZED, DOUBLE-BLINDED PHASE 3 STUDY TO DEMONSTRATE LOT-TO-LOT CONSISTENCY OF THREE LOTS OF A LIVE-ATTENUATED CHIKUNGUNYA VIRUS VACCINE CANDIDATE (VLA1553) IN HEALTHY ADULTS AGED 18 TO 45 YEARS | ||||||
| 02/15/2022 | Valneva Austria GmbH | — | — | Cash or cash equivalent | $876.83 | Research |
| Study: A RANDOMIZED, DOUBLE-BLINDED PHASE 3 STUDY TO DEMONSTRATE LOT-TO-LOT CONSISTENCY OF THREE LOTS OF A LIVE-ATTENUATED CHIKUNGUNYA VIRUS VACCINE CANDIDATE (VLA1553) IN HEALTHY ADULTS AGED 18 TO 45 YEARS | ||||||
| 02/08/2022 | Valneva Austria GmbH | — | — | Cash or cash equivalent | $3,486.78 | Research |
| Study: A MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLINDED PIVOTAL STUDY TO EVALUATE SAFETY AND IMMUNOGENICITY OF A LIVE-ATTEUATED CHIKUNGUNYA VIRUS VACCINE CANDIDATE (VLA1553) IN ADULTS AGED 18 YEARS AND ABOVE | ||||||
| 01/19/2022 | Valneva Austria GmbH | — | — | Cash or cash equivalent | $5,259.97 | Research |
| Study: A RANDOMIZED, DOUBLE-BLINDED PHASE 3 STUDY TO DEMONSTRATE LOT-TO-LOT CONSISTENCY OF THREE LOTS OF A LIVE-ATTENUATED CHIKUNGUNYA VIRUS VACCINE CANDIDATE (VLA1553) IN HEALTHY ADULTS AGED 18 TO 45 YEARS | ||||||
| 01/19/2022 | Valneva Austria GmbH | — | — | Cash or cash equivalent | $500.00 | Research |
| Study: A MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLINDED PIVOTAL STUDY TO EVALUATE SAFETY AND IMMUNOGENICITY OF A LIVE-ATTEUATED CHIKUNGUNYA VIRUS VACCINE CANDIDATE (VLA1553) IN ADULTS AGED 18 YEARS AND ABOVE | ||||||
| 01/11/2022 | Valneva Austria GmbH | — | — | Cash or cash equivalent | $3,350.00 | Research |
| Study: A MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLINDED PIVOTAL STUDY TO EVALUATE SAFETY AND IMMUNOGENICITY OF A LIVE-ATTEUATED CHIKUNGUNYA VIRUS VACCINE CANDIDATE (VLA1553) IN ADULTS AGED 18 YEARS AND ABOVE | ||||||
| 06/01/2019 | AstraZeneca Pharmaceuticals LP | — | Travel and Lodging | In-kind items and services | $88.70 | General |
| 06/01/2019 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $59.94 | General |
| 06/01/2019 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $48.66 | General |
| 06/01/2019 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $35.36 | General |
| 05/31/2019 | AstraZeneca Pharmaceuticals LP | — | Travel and Lodging | In-kind items and services | $1,527.61 | General |
| 05/31/2019 | AstraZeneca Pharmaceuticals LP | — | Travel and Lodging | In-kind items and services | $177.70 | General |
| 05/31/2019 | AstraZeneca Pharmaceuticals LP | — | Travel and Lodging | In-kind items and services | $141.25 | General |
| 05/31/2019 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $97.08 | General |
| 06/01/2017 | SANOFI-AVENTIS U.S. LLC | NO PRODUCT DISCUSSED (Drug) | Travel and Lodging | In-kind items and services | $6,204.86 | General |
| 06/01/2017 | SANOFI-AVENTIS U.S. LLC | NO PRODUCT DISCUSSED (Drug) | Travel and Lodging | In-kind items and services | $754.34 | General |
| 06/01/2017 | SANOFI-AVENTIS U.S. LLC | NO PRODUCT DISCUSSED (Drug) | Travel and Lodging | In-kind items and services | $231.85 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLINDED PIVOTAL STUDY TO EVALUATE SAFETY AND IMMUNOGENICITY OF A LIVE-ATTEUATED CHIKUNGUNYA VIRUS VACCINE CANDIDATE (VLA1553) IN ADULTS AGED 18 YEARS AND ABOVE | Valneva Austria GmbH | $78,701 | 7 |
| A RANDOMIZED, DOUBLE-BLINDED PHASE 3 STUDY TO DEMONSTRATE LOT-TO-LOT CONSISTENCY OF THREE LOTS OF A LIVE-ATTENUATED CHIKUNGUNYA VIRUS VACCINE CANDIDATE (VLA1553) IN HEALTHY ADULTS AGED 18 TO 45 YEARS | Valneva Austria GmbH | $41,364 | 5 |
| A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION | PFIZER INC. | $865.92 | 1 |
About Dr. John Ervin, MD
Dr. John Ervin, MD is a Rheumatology healthcare provider based in Kansas City, Missouri. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/24/2006. The National Provider Identifier (NPI) number assigned to this provider is 1376565549.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. John Ervin, MD has received a total of $130,602 in payments from pharmaceutical and medical device companies, with $865.92 received in 2023. These payments were reported across 27 transactions from 5 companies. The most common payment nature is "" ($120,931).
Ad
Practice Information
- Specialty Rheumatology
- Location Kansas City, MO
- Active Since 07/24/2006
- Last Updated 07/18/2007
- Taxonomy Code 207RR0500X
- Entity Type Individual
- NPI Number 1376565549
Products in Payments
- NO PRODUCT DISCUSSED (Drug) $7,460
- ZAVZPRET (Drug) $865.92
- CAPVAXIVE (Biological) $35.00
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Rheumatology Doctors in Kansas City
Dr. Mark Box, Md, MD
Rheumatology — Payments: $461,914
Rheumatology $461,914
Thomas Scott, M.d, M.D
Rheumatology — Payments: $163,330
Rheumatology $163,330
Dr. Shashank Radadiya, Md, MD
Rheumatology — Payments: $95,431
Rheumatology $95,431
Ghaith Noaiseh, Md, MD
Rheumatology — Payments: $21,392
Rheumatology $21,392
Cameron Jones, Md, MD
Rheumatology — Payments: $3,094
Rheumatology $3,094
Dr. David John, Md, MD
Rheumatology — Payments: $1,325
Rheumatology $1,325